Human Multiple Myeloma cell lines

A high risk signature has been established from the molecular heterogeneity of the HMCLs (Moreaux, Haematologica 2011)Over past decades, Myelomax founders have developed and characterized a large and unique (>30) collection of Human Myeloma Cell Lines (HMCLs) covering the molecular and  functional diversity of Multiple Myeloma.

 

Our collection of HMCLs is characterized for :

  • Phenotype

  • Chromosomal abnormalities
    • different recurrent 14q32 translocations
    • hyperdiploidy
    • deletion del(17)p
  • Global gene expression profile
    • molecular groups overlapping the ones of patients
  • K-Ras, N-Ras, TP53 mutations

  • Bcl2/Mcl1-BH3 complexes

 

which all reflect the one of the patients (Bataille, Haematologica 2006)

 

 

 

Our collection is functionally characterized for :

  • Response to therapeutic agents
    • Dexamethasone (Juge-Morineau, Br J Haematol 1995)
    • Melphalan (Gomez-Bougie, Oncogene 2005) - Download PDF
    • Bortezomib (Gomez-Bougie, Cancer Res 2007) - Download PDF
    • Lenalidomide (Amiot, EHA 2009) - Download PDF
    • AV1642 (IGF1R) (Descamps, J Immunol 2006) - Download PDF
    • Mapa/Lexatumumab (TRAILR) (Ménoret, Blood 2006) - Download PDF
    • ABT-737 (Bcl2) (Bodet, ASH2010) - Download PDF
  • Signalling pathways of the major Multiple Myeloma growth factors
    • IL-6/STAT-3/Mcl-1 (Puthier, Eur J Immunol 1999) - Download PDF
    • IGF-1/Akt (Descamps, J Immunol 2006) - Download PDF
  • Clonogenic growth factors
    • IL-6/IGF1/HGF (Collette, Eur Cytokine Network 2007) - Download PDF
    • IL21 (Ménoret, J Immunol 2008) - Download PDF
    • SCF (Chiron, ASH 2010) - Download PDF

 

 

Our collection has allowed the identification of biomarkers predictive of responses or associated with responses :

  • Melphalan, Bortezomib - Mcl1/Noxa (Gomez-Bougie, Oncogene 2005) - (Gomez-Bougie, Cancer Res 2007) - Download PDF
  • Lenalidomide - SKP2/p27 (Amiot, EHA 2009) - Download PDF
  • Trail-R agonists - p53 (Surget, IMW 2011) - Download PDF
  • Anti-IGF1R - CD45 (Descamps, J immunol 2006) - Download PDF
  • ABT-737 - Bcl2/Mcl1 ratio (Bodet, ASH 2010) - Download PDF
A high risk signature has been established from the molecular heterogeneity of the HMCLs (Moreaux, Haematologica 2011)
Download PDF- Download PDF

©Myelomax 2010 All rights reserved
RCS Nantes (FRANCE) 519 189 062 - APE 7219Z - SAS Capital 50 000€ | Mail : contact@myelomax.com
Designed by Absoludesign & Developed by la tête dans la toile